CellGen

Executive Summary

CellGen is a Netherlands-based biotechnology company focused on developing novel cell therapies for oncology and immunological disorders. Founded in 2016, the company has raised $105 million and employs 50-200 staff. Operating at the preclinical stage, CellGen is engineering immune cells such as T cells and NK cells to enhance anti-cancer activity and modulate immune responses. The company's approach combines advanced cell engineering with immunotherapy to target both solid tumors and hematologic malignancies. With a strong funding base and strategic location in Leiden, a hub for biotech innovation, CellGen is well-positioned to advance its pipeline. While still in early development, the company's focus on cutting-edge cell therapy modalities and substantial financial backing suggest significant potential. Near-term milestones are expected to include the filing of an Investigational New Drug (IND) application for a lead candidate, potentially targeting CD19 or other validated antigens, and initiation of Phase I clinical trials. The company may also pursue strategic partnerships to expand its platform or manufacturing capabilities. Given the preclinical stage and competitive landscape, conviction is moderate, but the sizable funding and experienced team provide a solid foundation.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Cell Therapy Candidate70% success
• Q1 2027Initiation of Phase I Clinical Trial60% success
• Q4 2026Strategic Partnership or Licensing Deal50% success